CureVac (NASDAQ:CVAC) Shares Down 0.1% - Here's Why

CureVac N.V. (NASDAQ:CVAC - Get Free Report)'s share price fell 0.1% during mid-day trading on Friday . The stock traded as low as $5.38 and last traded at $5.40. 751,012 shares changed hands during trading, a decline of 4% from the average session volume of 786,138 shares. The stock had previously closed at $5.40.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CVAC shares. Citizens Jmp lowered shares of CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. Jefferies Financial Group restated a "hold" rating and set a $5.00 target price (down previously from $7.00) on shares of CureVac in a report on Friday, June 13th. Citigroup cut CureVac to a "market perform" rating in a research report on Thursday, June 12th. UBS Group lowered CureVac from a "strong-buy" rating to a "neutral" rating and reduced their price target for the stock from $12.00 to $5.50 in a research report on Thursday, June 26th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $10.00 price objective on shares of CureVac in a research report on Wednesday, May 28th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, CureVac presently has an average rating of "Hold" and a consensus price target of $6.83.

CureVac Trading Up 0.2%

The company's 50 day simple moving average is $4.53 and its two-hundred day simple moving average is $3.77. The company has a quick ratio of 7.64, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 5.89 and a beta of 2.53.

CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). CureVac had a return on equity of 30.89% and a net margin of 35.44%. The business had revenue of $0.94 million during the quarter, compared to analyst estimates of $4.27 million. As a group, research analysts anticipate that CureVac N.V. will post 0.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CureVac

Hedge funds have recently modified their holdings of the stock. Signaturefd LLC boosted its stake in CureVac by 29.2% in the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company's stock worth $123,000 after purchasing an additional 8,170 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after buying an additional 22,491 shares during the period. Quadrant Capital Group LLC grew its holdings in shares of CureVac by 61.8% during the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock valued at $171,000 after buying an additional 19,098 shares during the last quarter. Barclays PLC increased its position in shares of CureVac by 51.8% in the 4th quarter. Barclays PLC now owns 34,836 shares of the company's stock valued at $118,000 after acquiring an additional 11,890 shares during the period. Finally, XTX Topco Ltd increased its position in shares of CureVac by 90.2% in the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock valued at $83,000 after acquiring an additional 11,553 shares during the period. Institutional investors and hedge funds own 17.26% of the company's stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.